Peter Attia discusses the use of trizepatide in his practice, noting that 15-20% of patients are on it. He contrasts current usage with five years ago, when semaglutide led to significant muscle loss, expressing a current view that these drugs can be used safely for long-term muscle health with deliberate attention to protein intake, often through liquid shakes. He emphasizes a "slow and steady" approach to dosing, preferring lower doses like 2.5mg to 7.5mg to avoid rapid weight loss and the "yo-yoing" effect. Attia and Rhonda Patrick also explore whether GLP-1 receptor agonists are geroprotective independent of weight loss, citing cases of patients with normal weight and metabolic dysfunction showing profound improvement on microdoses of trizepatide without weight loss. They also touch on anecdotal observations about injection sites affecting anorexic effects.
Sign in to continue reading, translating and more.
Continue
